GENEVA/KINSHASA — In a landmark development for global health security, the World Health Organization (WHO) has officially granted its first Emergency Use Listing (EUL) to a molecular diagnostic test for the Bundibugyo virus (BDBV). This critical milestone provides frontline health workers with a validated, high-precision tool to detect the pathogen’s genetic material in blood samples, marking a decisive shift in the ongoing battle against one of the world’s most lethal viral threats.
The EUL procedure serves as a rigorous vetting mechanism, evaluating the safety, quality, and clinical performance of essential health products. By fast-tracking these tools, the WHO aims to ensure that low- and middle-income countries—often the hardest hit by hemorrhagic fever outbreaks—are not left behind in the race for life-saving diagnostics.
The Core Facts: A New Weapon in the Diagnostic Arsenal
The newly listed molecular diagnostic test is designed to identify the BDBV virus at the genetic level, providing the rapid confirmation necessary to break chains of transmission. In the context of an Ebola-like outbreak, where symptoms can mimic other endemic diseases, the ability to confirm a diagnosis in hours rather than days is the difference between containment and catastrophe.
The EUL process is not merely a bureaucratic checkbox; it is a clinical safeguard. It ensures that diagnostic tools deployed in chaotic, resource-constrained environments meet stringent international standards. For governments and UN procurement agencies, this listing acts as a "seal of approval," providing the confidence needed to authorize the mass purchase and distribution of tests during a Public Health Emergency of International Concern (PHEIC).
Chronology of the 2026 Outbreak and Response
The urgency of this listing is underscored by the rapid, tragic evolution of the current outbreak.
- 17 May 2026: WHO Director-General Dr. Tedros Adhanom Ghebreyesus officially declared a Public Health Emergency of International Concern (PHEIC) regarding the surge of Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo (DRC) and neighboring Uganda. The declaration signaled a clear admission that the regional response required international mobilization.
- Late May 2026: Recognizing the bottleneck in diagnostic capacity, the WHO launched an urgent global call for Expressions of Interest (EOI) from manufacturers of in vitro diagnostics (IVDs) specifically tailored for BDBV.
- Mid-2026: As the death toll climbed, the WHO, in partnership with the Africa Centres for Disease Control and Prevention (Africa CDC), accelerated the vetting process.
- Present Day: The formal granting of the EUL for the first molecular test marks the culmination of this accelerated regulatory pathway, providing a standardized, reliable method for clinical confirmation.
Supporting Data: The Scale of the Crisis
The statistics surrounding the current BDBV outbreak are sobering. As of the latest reporting, the DRC has recorded 1,406 laboratory-confirmed cases, resulting in 438 deaths. These figures represent the largest recorded outbreak of the Bundibugyo strain, a virus known for its high mortality rate and tendency to spread through close contact with infected individuals or contaminated bodily fluids.
The Evolution of Testing Capacity
A critical component of the containment strategy has been the rapid scaling of laboratory infrastructure. At the onset of the outbreak, testing was dangerously centralized, relying primarily on the Institut National de Recherche Biomédicale (INRB) in Kinshasa and Goma. This centralized model could only process between 200 and 400 tests per day—a fraction of the required volume.
Through a coordinated effort involving the WHO, Africa CDC, and international partners, the testing network has undergone a massive expansion. Today, a robust network of 10 laboratories across the affected provinces boasts a combined capacity exceeding 2,000 tests per day. This six-fold increase in diagnostic throughput is essential for identifying asymptomatic or mild cases and ensuring that patient care is initiated before the virus spreads further into the community.
Official Responses: Science as a Shield
The significance of this EUL has been echoed by top health officials who emphasize that technology must be backed by rigorous oversight.
"Public health emergencies require not only speed, but also confidence that the health products being used meet standards for quality, safety, and performance," said Dr. Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data. "During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission. Through this Emergency Use Listing, WHO is helping countries access trusted diagnostic tools more rapidly so that they can respond more effectively."
The WHO’s commitment to this effort extends beyond a single product. The organization is currently reviewing additional applications for BDBV diagnostics. Furthermore, a joint validation platform is being established in collaboration with the Africa CDC and partners such as PATH, FIND, and CHAI. Supported by Unitaid, this platform aims to evaluate a variety of diagnostic technologies, including near-point-of-care molecular tests and antigen rapid diagnostic tests, to generate real-world clinical evidence in the heart of the outbreak zones.
Implications for Global Health Security
The granting of this EUL has profound implications for how the international community approaches future viral threats.
1. Decentralization of Care
By validating tests that can be deployed closer to the "point of need," the WHO is moving toward a model of decentralized surveillance. This reduces the burden on major research institutes and allows for faster triage at the local level.
2. Standardization of Regulatory Pathways
The EUL process has proven to be a flexible yet robust mechanism for addressing "diagnostic deserts." By streamlining the evidentiary requirements without compromising on safety, the WHO has provided a blueprint for how to handle future outbreaks of emerging or re-emerging infectious diseases.
3. Strengthening Regional Resilience
The collaboration between the WHO and the Africa CDC represents a shift toward empowering regional institutions. By investing in local lab networks, the response is now rooted in the geography of the outbreak rather than being directed entirely from international headquarters.
4. A Template for Future Emergencies
The theme of World Health Day 2026, "Together for health. Stand with science," is embodied in this initiative. It serves as a reminder that science is not merely an academic pursuit but the foundation upon which global health security is built. As the WHO continues to monitor the BDBV outbreak, the data generated by these new diagnostic tools will be vital in refining clinical care protocols and developing potential future vaccines or therapeutics.
Understanding the Pathogen: The Bundibugyo Virus
Bundibugyo virus (BDBV) is one of the three species of the Ebolavirus genus capable of causing large-scale, fatal outbreaks in humans. Its transmission dynamics are well-understood but notoriously difficult to control: the virus is transmitted from animal hosts to humans, subsequently spreading through human-to-human contact. Infection occurs through direct contact with the blood, secretions, organs, or other bodily fluids of infected people, or with surfaces and materials (like bedding or clothing) contaminated with these fluids.
Because the initial symptoms—fever, fatigue, muscle pain, and headache—are common to many tropical diseases like malaria or typhoid, the laboratory-based molecular test is the only definitive way to distinguish BDBV from other pathogens. Without such tests, hospitals are at risk of overcrowding with non-BDBV patients, and active BDBV cases may go undiagnosed, leading to further community transmission.
Looking Ahead: A Sustained Commitment
As the WHO continues its work with manufacturers, global partners, and national ministries of health, the focus remains on ensuring that these tools reach the people who need them most. The EUL webpage is being updated in real-time to provide transparency on pending applications and the availability of diagnostic supplies.
The success of this intervention is a testament to the power of international cooperation. While the 1,406 cases confirmed in the DRC represent a significant humanitarian challenge, the availability of a globally recognized diagnostic tool provides a path toward containment. The "Stand with Science" mantra adopted by the WHO in 2026 is not just a slogan—it is the strategy for navigating the complexities of modern, globalized disease threats.
For more information on the ongoing regulatory efforts and the latest developments in the BDBV response, stakeholders and the public are encouraged to visit the official WHO Diagnostic Procurement Portal.
About the World Health Organization
The World Health Organization (WHO) is the UN agency for health that connects nations, partners, and people on the front lines in over 150 locations. Dedicated to the well-being of all, the WHO provides the leadership necessary to prevent disease, address the root causes of health inequities, and ensure that every person, everywhere, has an equal chance at a healthy life. Through its scientific leadership, the WHO remains the primary architect of global health strategy, standing at the forefront of the fight against infectious diseases that threaten our shared future.
About the Author
